PTC Therapeutics, Inc. (PTCT) stock prices updated...
 

PTC Therapeutics, Inc. stock price

PTC Therapeutics, Inc. latest news:


  • 09/28/2017 17:13:44

    PTC Therapeutics gains after FDA panel votes against drug approval

    PTC Therapeutics Inc. stock gained 10% in after-hours action Thursday after trading was halted for the entire regular session as a Food and Drug Administration panel discussed the company's Duchenne muscular dystrophy drug. The panel eventually voted not to approve the drug, saying that more testing was required to prove its efficacy, though they did not completely reject the drug. The FDA does not have to follow the panel's recommendation, as it showed in controversially approving a drug for the same disease last year from Sarepta Therapeutics Inc. despite a panel recommendation against the approval. After being halted at Wednesday's closing price of $17.46 all day, PTC shares resumed trading just before 6 p.m. Eastern time Thursday and topped $19.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/28/2017 14:35:51

    UPDATE 2-PTC Therapeutics Duchenne drug may work, data inconclusive -FDA panel

    Sept 28 (Reuters) - PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

  • 09/28/2017 14:08:27

    UPDATE 1-PTC Therapeutics Duchenne may work, data inconclusive -FDA panel

    Sept 28 (Reuters) - PTC Therapeutics' experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

  • 09/28/2017 13:48:21

    FDA panel: PTC Therapeutics Duchenne drug data inconclusive

    Sept 28 (Reuters) - PTC Therapeutics' experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

  • More trends:

    Pulaski Financial Corp.PULB | Pulmatrix, Inc.PULM | Pure Cycle CorporationPCYO | QAD Inc.QADA | QAD Inc.QADB | QC Holdings, Inc.QCCO | QCR Holdings, Inc.QCRH | Qiagen N.V.QGEN | QIWI plcQIWI | QKL Stores, Inc.QKLS |